Recommandation pour la prise en charge d'une RTU
Traitement du syndrome myélodysplasique (SMD) avec thrombopénie symptomatique chez les patients ayant moins de 5% de blastes médullaires et de risque très faible, faible et intermédiaire selon le score R-IPSS).
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
jNgZL2uqr9EaCYLV
